Sagimet Biosciences Cash Flow Statement (2023-2024) | SGMT

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024
Operating Activities
Net Income -6.36M-8.15M
Share-based Compensation 0.77M1.06M1.85M1.31M0.76M1.45M1.55M
Gains from Sales and Divestitures 0.28M
Gains from Investment Securities -0.00M0.10M0.10M0.05M
Non-cash Items 21.31M1.78M0.01M0.01M2.46M2.31M
Cash from Operations -7.08M-5.72M-3.88M-7.08M-6.21M-5.63M-19.57M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.04M0.00M-0.00M0.19M0.48M0.53M
Change in Working Capital
Change in Accured Expenses -1.19M-0.40M1.39M0.32M-0.78M1.09M-1.66M
Other Working Capital Changes 0.04M-0.41M0.77M0.56M-0.64M-0.41M4.31M
Investing Activities
Change in Acquisitions & Divestments 19.40M12.80M3.00M7.79M12.00M
Cash from Investing Activities 19.40M12.80M-19.62M3.00M-75.16M0.62M
Financing Activities
Other financing activities 0.14M0.91M1.02M0.03M
Cash from Financing Activities -0.14M-0.91M87.21M104.85M-0.03M
Additional items
Change in Cash 12.18M6.17M83.33M-26.70M101.64M-80.82M
Beginning Cash Balance -12.18M12.34M18.51M101.84M75.14M176.78M77.01M
Free Cash Flow -7.08M-5.72M-3.88M-7.08M-6.21M-5.63M-19.57M
Net Cash Flow 12.18M6.17M83.33M-26.70M101.64M-80.82M-18.95M